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Abstract
Vitronectin is an abundant glycoprotein located in both the circulation
and the extra cellular matrix that surrounds tissues. Vitronectin has a myriad of
roles pertaining to cells, including implications in cell-cell adhesion, tumor
malignancy, cell migration, and fibrinolysis. To date, obtaining vitronectin
requires extensive preparation steps beginning with human plasma or the use of
virally-infected cells. Attempts at expression in a prokaryotic vector have been
largely unsuccessful. However, given that each of these methods has limitations
and risks, a eukaryotic expression system in Schneider 2 Drosophila cells was
used to allow for harvesting a large quantity of vitronectin in a properly
glycosylated form comparable to that produced in the human body. This
method allows for the production of a considerable amount of protein
(approximately 10-20 mg in a 450 mL cell culture) in as little as one to two weeks
from a maintained cell stock, and should be further investigated as a possible
replacement for the human plasma purification methods currently in use.
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In addition to the purification strategies and the methods and results of
the project, this thesis will discuss the specifics of how vitronectin influences the
fibrinolytic cascade of plasminogen activation by interacting with and stabilizing
plasminogen activator inhibitor 1 or PAI-1. This interaction makes vitronectin an
indirect, non-catalytic inhibitor of plasminogen proteolysis to active plasmin, an
enzyme that breaks down fibrin clots. By this cascade of interactions, vitronectin
is a contributor to the buildup of blood clots. Therefore, further understanding of
the vitronectin-PAI-1 complex, as well as possible interactions with metal ions, will
allow for considerable insight into conditions such as strokes, heart disease, and
blood clotting disorders. It is hoped that the availability of a recombinant
source of vitronectin will serve to expedite future studies into these diseases.

Introduction
Vitronectin is known to have a multitude of roles in the human body that
are the direct result of the diverse variety of ligands with which it interacts. A
glycoprotein of 459 amino acid residues, it occurs in two forms in the blood: a 75
kDa single peptide form and a disulfide-linked dimer of 65 kDa and 10 kDa
fragments (Tomasini and Mosher, 1986). The vast majority of vitronectin is
produced by liver hepatocytes, after which it is exported to the blood stream
along with many other platelet components where in circulates at
concentrations of around 0.2 mg/mL (Sano et al 2010). Prior to its transport into
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the blood, it is at times cleaved by an undetermined protease at arginine 379
toward its C-terminus to produce the 65 kDa form, which is often visible as a
separate species from the 75 kDa vitronectin during electrophoresis (Podor et al
2002).
While a crystal structure for vitronectin has yet to be produced, homology
modeling has been used to characterize its four different domains. Xu et al,
modeled the domains in 2001 by comparing them to other known structures
with similar sequences and motifs and using docking experiments. Vitronectin
consists of a 44-residue N-terminal domain known as the somatomedin B domain
(SMB), an intrinsically disordered region (residues 48-130), a central domain
(residues 131-323) with four beta-propeller domains, and finally a C-terminal
heparin-binding domain (residues 354-456). Between the SMB domain and the
disordered regions are the sites for the RGD integrin binding.
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Figure 2: The four domains of vitronectin. These structures are homology models
based on computational methods and direct experiments. Not shown is the
heparin binding site on the C-terminus, as well as the glycosylation sites near the
SMB domain. Image adapted from work by Xu et al, 2001.

Perhaps the most critical domain of vitronectin is the somatomedin B
domain (SMB). This domain contains the binding sites for PAI-1, uPAR, and
integrins (Mayasundari et al 2004). In fact, the crystal structure for PAI-1 in
complex with only the SMB domain has been solved, and is shown below. In
that circumstance, SMB was expressed as an isolated domain in E. coli.
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Figure 3: PAI-1 is shown here in complex with the SMB region of vitronectin. SMB is
shown in yellow. This crystal structure was produced by Zhou, et al in 2003.

Vitronectin was initially identified as a protein involved cell
adhesion, growth, and spreading in the extra cellular matrix (Holmes, 1967).
Since then it has been shown to be involved with cell adhesion via the Arg-GlyAsp (RGB) integrin binding motif (Gladson and Cheresh, 1991) as well as tumor
adherence (Carreiras et al 1999) and malignancy (Sidenius and Blasi, 2003) due
to its interactions with the urokinase plasminogen activator receptor (uPAR).
Another major area of interactions for vitronectin is its contributions to
maintaining hemostasis. Vitronectin binds heparin, an anticoagulant, and
impairs its ability to interact with thrombin and antithrombin (Preissner and
Berghaus 1986). This helps to promote the coagulation cascade, leading to the
conversion of fibrinogen to fibrin and the formation of clots. Vitronectin is
involved not only in helping to lead to the formation of fibrin clots, but also in
preventing the clots from breaking broken down, a process called fibrinolysis. It
does this by prolonging the active conformation of plasminogen activator
inhibitor 1, or PAI-1 (Schar et al 2008).
PAI-1 is a serine protease inhibitor, or serpin, which directly binds to and
inhibits tissue plasminogen activator and urokinase plasminogen activator, both
of which are serine proteases. In the absence of PAI-1, these two proteins would
normally cleave plasminogen to plasmin. Plasmin is a serine protease itself, and

Landers - 6

it dissolves the fibrin clots, effectively ending the coagulation event (Wiman and
Collen, 1978). Therefore, PAI-1 can be viewed as a factor that promotes the
longevity of fibrin clots. An interesting caveat of PAI-1 is its inherent
thermodynamic instability. With a half-life of approximately 60 to 70 minutes in
the blood, PAI-1 freely converts from its active conformation to an inactive form
(Chorostowska-Wynimko, Skrzypczak-Jankun, and Jankun, 2004). However,
vitronectin serves to stabilize the active conformation, thus allowing PAI-1 to
continue binding and inhibiting tissue plasminogen activator and urokinase
plasminogen activator. This interaction means that vitronectin prolongs fibrin
clots and coagulation events, and therefore any insights that can be gained
into the PAI-1 – Vitronectin interaction could be useful for understanding the
process of fibrinolysis as well as providing later targets for future drugs to treat
conditions such as heart disease and strokes.

Landers - 7

Figure 1: PAI-1 is shown inhibiting tissue plasminogen activator (tPA). tPA
converts plasminogen (PLG) to active plasmin, which degrades fibrin clots.
Vitronectin stabilizes PAI-1 in its active conformation, improving its ability to
inhibit tPA and uPA. (Image adapted from Krone, Allen, and McCrae, 2010.)

Given the great importance of vitronectin to human health and its variety
of roles in the body, the availability of a practical recombinant source of the
protein would be extremely beneficial. However, several features of vitronectin
make this somewhat difficult. First, vitronectin has over 400 amino acid residues,
which makes it difficult to produce in a prokaryotic vector compared to the
relative ease with which many recombinant proteins (PAI-1 for example) can be
produced. Furthermore, since vitronectin contains three gylcosylation sites,
which account for as much as 30% of its mass (Schvartz, Seger, and Shaltiel,
1999), an expression system with proper eukaryotic glycosylation is preferred.
Another alternative is to use virally infected Sf9 or Hi5 cells (Schar et al 2008). This
method indeed produces functional protein; however, this does not represent a
stable cell line, and the yields of such a production system are relatively low.
The current method used to produce native vitronectin is to purify it from
human blood plasma. The process itself is time consuming (typically 3-5 weeks
of work) and expensive, and it has the inherent risks of manipulating pooled
human plasma from donors. Furthermore, while this method yields very large
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amounts of protein, it does not allow for any mutagenesis to be performed. As
will be explained later in this thesis, this proposed system of expressing vitronectin
in a stable line of Schneider 2 Drosophila cells produces a large amount of
protein, in a form that appears to be comparable to native human, in a timespan that is significantly less.

Purification from
human blood
plasma
Viral Infection
Recombinant
Prokaryotic
Expression (E. coli)
Recombinant
Eukaryotic
Expression (S2
Drosophila)

Post Translational
Modification
Yes

Time Required

Yes
No, protein too
large

1-2 weeks
1 week

~ 500 ug
None Usable

Yes

5-10 days from
maintained cell
line

5-25 mg from a
450 mL S2 Culture
at 2 x 107 cells/mL.

3-5 weeks

Amount
Generated
10-50 mg from 10
plasma bags

Table 1: Comparison of methods to acquire vitronectin. An added benefit of a
recombinant system is the ability to perform mutagenesis experiments ranging
from single amino-acid modifications to full domain deletions. An outline of the
scheme used to produce the results in the last row is proposed in the next
section.

A recent attempt in the Peterson laboratory at creating a recombinant
source of vitronectin has been met with some success. Dr. Lawrence Thompson
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helped to develop the method described here, providing the foundation for this
work with some important distinctions. One concern was whether or not
vitronectin would form higher order complexes within or immediately after
excretion from the cell. For these reasons, Dr. Thompson chose to add a Kringle
domain to the protein, with the expectation that after purification, the domain
could be cleaved away using proteases. These domains are common in blood
coagulation factors (plasminogen, prothombin, and apolipoprotein, for
example), and are believed to regulate proteolytic interactions (Patthy et al,
1984). An added benefit is that Kringle domains bind lysine and therefore lysine
columns with a high affinity, which facilitate purification (Chang et al, 1998).
In this method, stable cell lines of S2 Drosophila were developed that
produced both vitronectin and a mutant form lacking the somatomedin B
domain. These proteins were purified using a lysine column, and 15 mg of
protein was generated from five liters of cells at a density of ~106 cells/mL Note.
However, despite successful purification of the proteins, removal of the kringle
domain was recalcitrant to all efforts. Some proteases cleaved away the kringle
domain but also cleaved sites in vitronectin, while others did not cleave the
domain at all. It was decided that a new strategy forgoing the kringle domain
and using the poly-histidine tag for purification should be attempted, and the
procedure in this thesis was the result.
Note

The concentration of S2 cells here is approximately 20-fold less than that used in the expression described later.
This was due to poor cell growth in large four liter containers used in this particular expression. This may have been
due to the cells being too dilute when passaged into the large containers, which could have starved them of
necessary growth factors. Based on that, smaller cultures at higher concentration (see methods section) are
recommended for any future work, as the larger cultures do not seem ideal for S2 growth.
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Materials, Methods, and Results
Materials – Drosophila Schneider 2 Cells were obtained from Invitrogen, as
was the pMT/BiP/V5-His C vector chosen for the transfection of the S2 cells.
Transfection of the S2 line was completed using Invitrogen’s calcium phosphate
transfection kit and protocol. Additionally, pCoBlast selection vector from
Invitrogen was also used to generate the stable cell line and select for
transfected cells. All S2 cultures were grown in Hyclone SFX Insect Media from
Thermo Scientific. Depending on the circumstance (see next section), some
cultures were supplemented with fetal bovine serum from Gibco, PenicillinStreptomycin from Gibco, and/or Blasticidin S from Invitrogen.
The S2 cell line is derived from embryonic Drosophila and exhibit
characteristics that suggest they are derived from a macrophage lineage
(Schneider, 1976). The pMT vector itself contains several useful features
designed to work with S2 cells that are ideal for vitronectin expression. First, it
contains restriction sites that are distinct from any sequences in vitronectin itself.
Secondly, it codes for a BiP (Binding Immunoglobulin Protein) signal sequence,
which targets the protein for excretion via the endoplasmic reticulum (Walter
and Johnson, 1994). This excretion is also useful since much of the
posttranslational modification vitronectin experiences will occur in the Golgi
apparatus and ER. Furthermore, this plasmid also codes for a poly-histidine C
terminal tag. This tag will allow for purification later on a Nickel-chelating
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Sepharose - Fast Flow resin column from Amersham Biosciences. Finally, the
plasmid contains a Drosophila metallothionein (MT) promoter site and a
polyadenylation signal, which will allow for efficient transcription and translation
of vitronectin, respectfully.

Figure 4: The pMT vector from Invitrogen. This vector has several features that
make it useful for vitronectin expression. For ligation into this plasmid, the Sma I
and Age I restriction sites were used.

For all preparations of DNA plasmids, Wizard Plus SV Miniprep DNA
Purification kits and protocol were used from Promega. Initial screening of
vitronectin sequences was completed in TOP10 E. Coli from Invitrogen using the
PCR 2.1 vector and its accompanying kit.
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Methods – Using the vitronectin template from Dr. Thompson’s earlier
endeavors, a polymerase chain reaction was performed to generate DNA for
both vitronectin (VN) and a mutant form lacking the Somatomedin B domain
(∆SMBVN). This was accomplished by using the primers shown below:

VN
CCCGGGACCAAGAGTCATGCAAGGG

∆SMBVN
CCCCGGGGTGTTCACTATGCCGGAGG

Forward
Primer
5’ to 3’
Reverse ACCGGTCAGATGGCCAGGAGCTGGGC ACCGGTGGGCTGAGGTCTCCCTGGAT
Primer
5’ to 3’

Table 2: Both forward primers include recognition sites for the Age I (ACCGGT)
restriction endonuclease, while the reverse primers have a site for the Sma I
(CCCGGG) restriction endonucleases. For ∆SMBVN, after the restriction site, the
primer begins at the intrinsically disordered domain (IDD).

Following the PCR reaction, VN and ∆SMBVN DNA were ligated into
respective PCR 2.1 vectors and used to transform TOP10 E. Coli. Transformed
cells were then plated on plates containing ampicillin and kanamycin.Note 2 The
PCR 2.1 vector enables a blue/white screen in which any insert into the plasmid
disrupts the beta-galactosidase gene. Upon treatment with X-gal, transformed

Note 2

Unlike other cell lines, including TOP10F’ (Invitrogen), TOP 10 do not require IPTG or any other reagent to
induce expression of galactosidase since it lacks the lac repressor.
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colonies lacking an insert will appear blue as X-gal is degraded by
galactosidase to form a colored product, while colonies with an insert and the
plasmid will be both antibiotic resistant and white from a lack of X-gal
processing. Individual white colonies were selected, grown in 15 mL Terrific Broth
cultures, and their plasmids isolated using a Wizard Plus SV Miniprep kit. The
plasmids were subject to DNA sequencing until plasmids without any mistakes in
the sequences for both VN and ∆SMBVN were obtained.
Next, the plasmids and pMT vectors were digested using Sma I and Age I,
gel purified to ensure only digested plasmid and sequences remained, and then
ligated together to form two pMT vectors, one containing the vitronectin
sequence and one the ∆SMB vitronectin sequence. These were again screened
and sequenced. Following each confirmed sequence, 25% glycerol stocks were
made and stored at –80o C.
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Figure 5: 0.8% Agarose electrophoresis gels. The gel on the right was used for gel
purification by physically excising the bands from the gel and purifying them to
yield pure, digested DNA with overhangs for ligation.

Schneider 2 Drosophila 1 mL cultures were thawed from liquid nitrogen
storage and added to 25 mm2 flat bottom flasks along with 4 mL of Hyclone SFC
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Insect Media + 50 units/mL Penstrep + 10% FBS (v/v).Note 3 These cultures are
stored in 10% DMSO, which needed to be removed to promote cell growth. The
cells were allowed to adhere to the surface of the flask for around one hour,
and then by tilting the flask, removing the media by pipetting, and quickly
adding fresh media (again, with FBS), the majority of the DMSO is removed.
These cultures were allowed to grow and were gradually passaged until the
transfection was performed. Cells were seeded at 106 cell/mL concentration in
35mm well plates, and a calcium phosphate transfection was performed
according to the protocol in the Invitrogen S2 Drosophila and pMT/Bip/V5-His
A,B,C kit.
Initially, only a transient transfection of the S2 cells was completed to
quickly screen the effectiveness of the vector in the cells. However, no
significant protein could be detected on SDS-Page Gels, nor could it be
detected using a GFP-pMT positive control that would fluoresce if GFP was
being produced. Assuming that this meant transfection efficiency was low, a
stable cell line transfection was begun to select for only cells that were cotransfected with the pCOBlast plasmid. Cells were again seeded on 35 mm well
plates, and the transfection was performed. Three days post transfection,
Blasticidin containing media (25 ug/mL) was added to the wells in place of the
original media. This media still contained FBS, but now had a selection agent to
Note 3

Whether or not FBS is added to the media is dependent on the next step in the process. Preparing cells for
transfection or selection requires the use of the FBS, since without it cell growth is initially slow and they may lack
proper nutrients to grow well under selection pressure. However, when cells stabling expressing protein are thawed,
one option is to forgo FBS, since cells will need to be weaned off it prior to inducing expression. This does result in
slower initial growth, but it also saves the time of weaning the cells.
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kill any cells that were not resistant to blasticidin. The concentration of cells in all
of the wells was routinely measured, and a control, a line that would eventually
produced vitronectin, and a line that would eventually produce deltaSMB
vitronectin are shown below graphically. Every three to five days the media was
removed without disturbing the cell layer, and fresh media was added. After
almost 4 weeks, larger cultures of the successfully transfected cell lines were
started.

Figure 6: Cells without Blasticidin S resistance (Untransfected) are quickly killed
following the addition of blasticidin. Even in wells where transfection occurred,
the vast majority of cells appeared to not be resistant. However, after many
days at a concentration so low that only a marginal percentage of cells were
alive, ∆SMBVN transfected cells and VN transfected cells resistant to blasticidin
began to proliferate.
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The new cell lines were renamed S2VN∆SMBCL1 and S2VNCL1 to
distinguish them from previous kringle-VN producing cell lines, and larger flat
bottom flask cultures and eventually larger scale shaker flask cultures were
grown. As the cultures were scaled up, Hyclone SFX Media was added without
FBS (though Blasticidin S and Penstrep were maintainedNote 4), a process that
weaned the cells so that the proteins in FBS would not be present in any future
analyses. After the cells reached a high concentration in 125 mL cultures, some
initial screening for protein production was completed, while larger cultures of
450 mL to 600 mL were also made. In either case, both were induced with 500
uM Copper Sulfate (making use of the metallothionein promoter in the pMT
vector).

Note 4

Typically, Penstrep was left in all cultures no matter the size. However, due to its cost, blasticidin was only
used for small-scale cultures. Despite the selection processing being complete, blasticidin is also potently
antimycotic (Izumi et al 1991). Its use in small-scale cultures prevents contamination. In addition to using
blasticidin, all work with S2 cells should always be performed in a laminar flow hood.
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Figure 7: For both S2VN∆SMBCL1 and S2VNCL1 cell lines, the growth of the cells
were comparable to the 24 hour doubling rate reported by Invitrogen.

Approximately thirty hours after induction, cell cultures were centrifuged
at 1000 X g to pellet the cells, and then the media was decanted and filtered
using a .22uM Corning Vacuum Filter Flask. An initial sample of the media was
collected to see if the cell lines expressed vitronectin and ∆SMBVN as hoped,
and to see if they secreted the product. BCA assays were also performed on
the media at this point to assess total protein, determining there to be 83 mg of
protein in one particular 450 mL culture. While the majority of this is likely not
vitronectin, that vitronectin is the dominant species (as seems to be the case in
Figure 8) bodes well for the method. After the proteins were determined to be
vitronectin and ∆SMBVN, permanent cell stocks able to express each were
frozen in liquid nitrogen according to Invitrogen’s protocol for freezing
permanent Schnedier 2 Drosophila cell cultures. To be certain the cells were still
viable after freezing, an aliquot of both S2-VN and S2-∆SMBVN cells were
thawed several weeks later and again tested for growth and expression. The
thawed cells showed growth and expression virtually identical to those
described throughout the remainder of this method.
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Figure 8: SDS-Page Acrylamide Reducing gel. The two S2 cell lines were shown to
be expressing vitronectin and ∆SMB as hoped. The concentrations shown are
relative to the media, and both appear to be the dominant protein species in
the media.

After the protein SDS-Page gel confirmed that the cells secreted the
desired proteins, the media containing the expressed full-length vitronectin was
dialyzed for 48 hours into 20 mM Imidizole, 50 mM NaH2PO4, and 500 mM NaCl at
pH 7, the buffer to be used for purification on a nickel column. Initially, a
gradient of 50 mM imidizole to 500 mM imidizole was used to purify the protein;
however, the gradient produced a gradual elution without any true peaks.
Instead, a multi-wash system was used. After the pooled protein from the
previous gradient was loaded on to the Nickel-chelating Sepharose Fast Flow
column, a 30 mM imidizole, 50 mM NaH2PO4, and 500 mM NaCl, pH 7 wash was
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run, followed by a 60 mM imidizole, 50 mM NaH2PO4, and 500 mM NaCl, pH 7
elution, followed by a 500 mM Imidizole, 50 mM NaH2PO4, and 500 mM NaCl pH
7 elution.
A reducing gel showed that the composition of the 60 mM imidizole and
500 mM imidizole elutions were indistinguishable, so they were pooled together
and concentrated. It should be noted that during this purification there was a
substantial amount of vitronectin that did not bind the column and came out in
the flow through. To help mitigate this, the flow through was run over the
column again and the elutions repeated. Another BSA assay was performed,
which indicated 3.6 mg of protein had been purified. This amount seems low
relative to the high amount measured in the original media, but it is suspected
that much of it was lost in the gradient attempt and in the lack of binding in the
flow through.
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Figure 9: Elutions of Vitronectin in three concentrations of Imidizole buffer as
described above. It is worth noting that considerable amounts of the protein
failed to bind to the nickel column. This could be due to a chelating agent in
the media that was not dialyzed out.

Figure 10: Western blot made using Rabbit Anti-VN antibodies conjugated to
Peroxidase labeled anti-rabbit antibodies. The double banding pattern is
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typical of human purified vitronectin as described in the introduction, indicating
that the proteolysis that occurs could be common to many animal cells.

Despite the relative success of the vitronectin purification scheme, a
sample of unpurified ∆SMBVN was run over both DEAE Sepharose column and a
SP column. Under neither circumstance was there significant binding of the
protein to the column.

Absorbance
at 280

280 Absorbance vs Fraction for
deltaSMB on SP Column
0.12
0.1
0.08
0.06
0.04
0.02
0
0

10

20

30

40

50

60

70

80

90

100

Fraction
Figure 11: While slight peaks were observed on the SP column, the low value of
the absorbance indicates that little bound. To be certain, a reducing and nonreducing SDS Page Gel was made to see what protein species were eluted.

Landers - 23

Figure 12: After concentration of the pooled fractions listed above from the SP
column, a reducing and non-reducing SDS Page Gel was run to further examine
higher order complexes. It would appear that in the case of ∆SMBVN very little
of the protein existed outside of the complexes.

Additionally, ∆SMBVN purified from the nickel column did not show
reactivity with anti-VN antibodies during western blots. Furthermore, it appeared
to have very large amounts of higher order complexes. Purified vitronectin also
exhibited large complexes in addition to the 65 kDa and 75 kDa bands, and it is
unclear if those are another protein in complex with vitronectin or larger
aggregates of vitronectin and ∆SMBVN themselves. An attempt was made to
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purify vitronectin from the larger complexes using a S-200 size exclusion column.
However, the larger complex and vitronectin appeared to elute at the same
time. This would seem to indicate that at least some of the purified vitronectin is
in complex with another molecule or with large complexes of itself, and that the
two may not be able to be separated at this stage in the purification.

Figure 13: After the use of a size exclusion column, the larger higher-order bands
are still clearly visible on this SDS Page Gel of Vitronectin. This indicates that
there is likely a large complex being formed that causes the two to elute
together.
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Discussion and Future Directions
These results indicate that a large amount of vitronectin and the ∆SMB
mutant can be produced in S2 Drosophila cells. Based on the findings, it would
seem that the best course of action would be to immediately dialyze all
unpurified samples after a 24 to 48 hour induction and cell removal, followed by
nickel column purification and 3 elutions of 30 mM imidizole, 50 mM NaH2PO4,
and 500 mM NaCl, pH 7; 60 mM imidizole, 50 mM NaH2PO4, and 500 mM NaCl,
pH 7; and 500 mM Imidizole, 50 mM NaH2PO4, and 500 mM NaCl pH 7. In light of
the lack of binding of the protein to the DEAE column and SP column, it is not
recommended that ion exchange be used without a new rational not known at
the time of this writing. One option may be to use a vitronectin-specific
antibody column immediately, followed by, or in place of, the nickel chelating
Sepharose column. The key will be finding a way to prevent both aggregation
and complex formation with other proteins in the media.
It should be noted that several other samples of unpurified protein, even
when left at 4oC for a few days, almost universally were problematic for later
purification attempts. For example, one sample appeared to have been
proteolyzed during the wait, so from then on a protease inhibitor cocktail was
added to all samples. This practice should be continued for all future
purification strategies. Additionally, purification of the protein should occur as
quickly as possible to prevent aggregation, if that is indeed the problem. Based
on the 83 mg of protein measured by the BCA assay in the unpurified media, this
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method appears to have great promise as a source of recombinant vitronectin
and ∆SMBVN so long as a method for removing or preventing the high order
complexes can be developed and the purification process can be streamlined.
In addition to improving the strategy for purifying these recombinant
proteins, surface plasmon resonance (SPR) studies of recombinant vitronectin
and ∆SMB vitronectin are recommended. SPR analysis will allow for the binding
constants between vitronectin and PAI-1 to be measured (Pattnaik 2005), and
compared to those of human purified vitronectin. An added benefit of SPR is
that the protein does not need to be completely pure, which may be useful
given the difficulty of removing the large molecular weight complexes.
Additionally, assays assessing the effects of recombinant vitronectin on PAI-1
stability could help to confirm that the interaction between the two is consistent
with what is observed in human purified vitronectin. If the constants for fulllength recombinant vitronectin is comparable to those of human purified
vitronectin, and if the purification strategy for the recombinant form can be
improved, then a genuine recombinant source of vitronectin will have been
created that is both practical, reliable, and considerably more efficient than
current methods. This would open the door to future mutagenesis studies, as
well as allowing for more frequent analyses of full-length vitronectin due to it
being more easily produced. Hopefully, by developing this recombinant source
that makes vitronectin easier to obtain, future insights into strokes, heart disease,
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tumor malignancy, and many other diseases may be expedited, paving the
way for new drugs to treat these conditions.
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